# Chronic Lymphocytic Leukemia Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenström macroglobulinemia. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11157 |
| Works | 252 |

## Topic papers all

Showing 15 of 252.

- [International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop](https://scholariq.org/papers/international-consensus-statement-on-preliminary-classification-criteria-for/)
- [Genetics of rheumatoid arthritis contributes to biology and drug discovery](https://scholariq.org/papers/genetics-of-rheumatoid-arthritis-contributes-to-biology-and-drug-discovery/)
- [A History of Cancer Chemotherapy](https://scholariq.org/papers/a-history-of-cancer-chemotherapy/)
- [Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/addition-of-rituximab-to-fludarabine-and-cyclophosphamide-in-patients-with/)
- [2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis](https://scholariq.org/papers/2012-update-of-the-2008-american-college-of-rheumatology-recommendations-for-the/)
- [European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia](https://scholariq.org/papers/european-leukemianet-2020-recommendations-for-treating-chronic-myeloid-leukemia/)
- [Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci](https://scholariq.org/papers/genome-wide-association-study-meta-analysis-identifies-seven-new-rheumatoid/)
- [Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study](https://scholariq.org/papers/lymphoproliferative-disorders-in-patients-receiving-thiopurines-for-inflammatory/)
- [A family of human cdc2‐related protein kinases.](https://scholariq.org/papers/a-family-of-human-cdc2-related-protein-kinases/)
- [APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy](https://scholariq.org/papers/apol1-genetic-variants-in-focal-segmental-glomerulosclerosis-and-hiv-associated/)
- [Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study](https://scholariq.org/papers/early-relapse-of-follicular-lymphoma-after-rituximab-plus-cyclophosphamide/)
- [The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia](https://scholariq.org/papers/the-lymph-node-microenvironment-promotes-b-cell-receptor-signaling-nf-b/)
- [CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes](https://scholariq.org/papers/cd28-dependent-rac1-activation-is-the-molecular-target-of-azathioprine-in/)
- [Treat-to-target in systemic lupus erythematosus: recommendations from an international task force](https://scholariq.org/papers/treat-to-target-in-systemic-lupus-erythematosus-recommendations-from-an/)
- [Global epidemiology of rheumatoid arthritis](https://scholariq.org/papers/global-epidemiology-of-rheumatoid-arthritis/)

## Topic primary papers

Showing 15 of 70.

- [Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/addition-of-rituximab-to-fludarabine-and-cyclophosphamide-in-patients-with/)
- [A family of human cdc2‐related protein kinases.](https://scholariq.org/papers/a-family-of-human-cdc2-related-protein-kinases/)
- [The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia](https://scholariq.org/papers/the-lymph-node-microenvironment-promotes-b-cell-receptor-signaling-nf-b/)
- [Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia](https://scholariq.org/papers/long-term-results-of-the-fludarabine-cyclophosphamide-and-rituximab-regimen-as/)
- [<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia](https://scholariq.org/papers/i-tp53-i-mutation-and-survival-in-chronic-lymphocytic-leukemia/)
- [Common variants at CD40 and other loci confer risk of rheumatoid arthritis](https://scholariq.org/papers/common-variants-at-cd40-and-other-loci-confer-risk-of-rheumatoid-arthritis/)
- [Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia](https://scholariq.org/papers/chemoimmunotherapy-with-fludarabine-cyclophosphamide-and-rituximab-for-relapsed/)
- [Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial](https://scholariq.org/papers/gene-mutations-and-treatment-outcome-in-chronic-lymphocytic-leukemia-results/)
- [Translocation and Rearrangements of the c- <i>myc</i> Oncogene Locus in Human Undifferentiated B-Cell Lymphomas](https://scholariq.org/papers/translocation-and-rearrangements-of-the-c-i-myc-i-oncogene-locus-in-human/)
- [Ibrutinib for chronic graft-versus-host disease after failure of prior therapy](https://scholariq.org/papers/ibrutinib-for-chronic-graft-versus-host-disease-after-failure-of-prior-therapy/)
- [Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-in-combination-with-rituximab-for-previously-untreated-patients/)
- [Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia](https://scholariq.org/papers/lenalidomide-induces-complete-and-partial-remissions-in-patients-with-relapsed/)
- [Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up](https://scholariq.org/papers/monoallelic-tp53-inactivation-is-associated-with-poor-prognosis-in-chronic/)
- [Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-combined-with-rituximab-in-patients-with-relapsed-and-or-refractory/)
- [Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia](https://scholariq.org/papers/clonal-evolution-leading-to-ibrutinib-resistance-in-chronic-lymphocytic-leukemia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.